查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995562

白血球分離術市場：按組件、疾病、技術、應用和最終用戶分類－2026-2032年全球市場預測

Leukapheresis Market by Component, Disease Indication, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年白血球分離術市場價值為 6,779 萬美元，預計到 2026 年將成長至 7,945 萬美元，複合年成長率為 12.23%，到 2032 年將達到 1.5208 億美元。

主要市場統計數據
基準年 2025 6779萬美元
預計年份：2026年 7945萬美元
預測年份 2032 1.5208億美元
複合年成長率 (%) 12.23%

白血球分離術正逐漸成為血液學、免疫學和再生醫學交叉領域的重要診療平台，滿足診斷和治療的雙重需求。隨著臨床團隊日益依賴分離術獲得的細胞產品進行細胞治療和免疫監測，醫療機構必須權衡操作的複雜性與臨床效益。儘管技術創新降低了應用門檻，但監管和報銷環境仍在影響醫院、專科診所和研究中心的應用格局。

近年來，醫療專業人員和採購負責人比以往任何時候都更加重視設備互通性、流程標準化和供應鏈韌性。這些優先事項正在加速設備製造商、耗材供應商和臨床研究機構之間的合作，以確保細胞採集和處理的可重複性。此外，細胞治療計畫的興起也使營運重點轉向將血球分離系統與下游生產流程整合，從而提高了設備和耗材品管的重要性。

展望未來，計畫負責人需要應對不斷變化的臨床適應症、連續流和間歇流技術的整合以及人才培養等問題，以實現服務範圍的永續擴展。為此，相關人員正優先考慮模組化解決方案，這些方案不僅支持診斷性血液分析、免疫監測和治療性血液採樣，還能促進幹細胞科學和腫瘤學領域的研究應用。

臨床需求、設備創新和監管重點的重大變革正在重新定義白血球分離術實踐和籌資策略。

白血球分離領域正經歷一場變革性的轉變，其驅動力包括臨床需求、技術發展和監管重點等多種因素。隨著細胞療法的日益成熟，臨床團隊正將適應症從傳統的血液學應用擴展到更廣泛的自體免疫疾病和腫瘤治療領域，促使儀器和耗材供應商進一步提升產品的性能、易用性和安全性。這種變革體現在旨在簡化工作流程、提高患者舒適度的系統數量激增，以及能夠提供即時過程指標以支持品質保證的監測儀器的湧現。

美國近期關稅趨勢對白血球分離和血液採集作業的採購計畫、供應鏈策略和設備採購的影響。

美國近期貿易政策調整和關稅變動，為整個白血球分離術生態系統的供應鏈和採購計畫帶來了新的考量。進口關稅和商品分類的變化會影響零件、設備和成品，並可能逐步增加某些耗材和設備的總成本。因此，醫院採購團隊和研究機構正在重新審視籌資策略，以在確保關鍵物資供應不間斷的同時，保持預算的柔軟性。

全面的細分洞察，揭示了驅動產品和服務策略的組件、應用、最終用戶、疾病適應症和技術優先事項。

對於致力於將產品開發和服務交付與臨床及研究需求相契合的相關人員，深入了解各細分領域的促進因素至關重要。基於組件，我們檢視了耗材和儀器的整體情況，其中耗材進一步細分為抗凝劑和試劑盒，儀器則分為血球分離系統和監測設備，並重點關注標準化和品管影響最大的領域。基於應用，該生態系統涵蓋診斷、研究和治療用途。診斷領域深入研究血液分析和免疫監測，研究領域涵蓋細胞療法和幹細胞研究，治療領域則涵蓋自體免疫疾病和腫瘤適應症，展現多樣化的端到端工作流程和不同的監管要求。

影響美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略考量，這些因素塑造了招募、服務和證據策略。

區域趨勢對整個白血球分離血液採集價值鏈中的應用、報銷途徑和策略夥伴關係有顯著影響。在美洲，成熟的供應鏈和完善的服務基礎設施，以及臨床網路和大規模醫院系統，往往推動了血球分離術融入治療通訊協定和細胞治療計畫。這為臨床研究人員和產業合作夥伴之間的可擴展應用和合作創造了有利環境。

醫療設備製造商、耗材供應商和服務供應商之間的關鍵企業策略和夥伴關係模式，旨在加速臨床整合和營運韌性。

醫療設備、耗材和服務領域的領導者正致力於將產品開發與臨床工作流程結合，以降低操作複雜性並提高資料連續性。製造商日益重視與電子健康記錄和實驗室資訊系統的互通性，以確保從樣本收集到下游流程的可追溯性。同時，耗材供應商則專注於試劑盒標準化和抗凝血劑最佳化，以降低細胞產量波動並提高與細胞治療生產流程的兼容性。

為行業高管提供可操作的建議，以協調臨床表現、供應鏈韌性和商業性柔軟性，從而實現可擴展的白血球分離計劃。

產業領導者應採取多管齊下的策略，平衡臨床療效、供應鏈韌性和商業性柔軟性，以創造長期價值。首先，投資於互通性和資料收集能力，確保從源頭到下游流程的可追溯性，從而加強臨床證據的累積和監管合規性。其次，透過探索區域供應商認證和近岸外包機會，實現採購多元化，降低貿易政策變化帶來的風險，並縮短關鍵耗材的前置作業時間。

調查方法結合了對關鍵相關人員的訪談、對二手技術文獻的審查以及監管分析，以確保獲得可操作和檢驗的見解。

本研究結合了對臨床負責人、採購專家和設備工程師的訪談，並輔以對臨床試驗註冊資料、監管申報文件和同行評審文獻的二次分析，建構了白血球分離術現狀的多面向視圖。主要研究包括與醫院血庫主任、細胞治療計畫負責人和研究機構管理人員進行結構化討論，以檢驗營運挑戰、採購重點和臨床整合重點。

結論：整合臨床、營運和商業性需求，指導白血球分離計畫的永續擴展和實施。

總之，白血球分離方法正處於策略轉折點，在臨床需求、技術創新和供應鏈趨勢的共同驅動下，其發展將塑造未來的專案模式。隨著診斷和治療應用的融合，我們需要能夠實現可重複的血液採集、可靠的監測以及與下游生產和檢測流程無縫銜接的儀器和耗材。同時，不斷變化的貿易政策和醫療環境的區域差異也要求採購團隊和供應商採用更具彈性的採購系統和商業性適應性強的方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：白血球分離術市場：依組件分類

  • 消耗品
    • 抗凝血劑
    • 成套工具
  • 裝置
    • 血液分離系統
    • 監控設備

第9章：白血球增多症治療市場：依疾病適應症分類

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 白血病
  • 固態腫瘤

第10章 白血球分離術市場：依技術分類

  • 連續流
  • 間斷流

第11章 白血球分離術市場：依應用領域分類

  • 診斷
    • 血液分析
    • 免疫療法
  • 研究
    • 細胞療法
    • 幹細胞研究
  • 治療
    • 自體免疫
    • 腫瘤學

第12章：白血球分離術市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第13章：白血球分離術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：白血球分離術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：白血球分離術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國白血球分離術市場

第17章 中國白血球分離術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allcells, LLC
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Beijing Zksk Technology Co. Ltd.
  • Bioivt
  • Caltag Medsystems Limited
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Discovery Life Sciences
  • Fresenius Kabi AG
  • Guangzhou Daji Medical Science and Technology Co. Ltd.
  • Haemonetics Corporation
  • Intelligent Tissue Group
  • Lonza Group Ag
  • Macopharma SA
  • Medica Spa.
  • Miltenyi Biotec GmbH
  • Precision for Medicine, Inc.
  • Puriblood Medical Co. Ltd.
  • Stemexpress, LLC
  • Terumo BCT
  • Zenbio, Inc.
Product Code: MRR-FD3F12D52871

The Leukapheresis Market was valued at USD 67.79 million in 2025 and is projected to grow to USD 79.45 million in 2026, with a CAGR of 12.23%, reaching USD 152.08 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 67.79 million
Estimated Year [2026] USD 79.45 million
Forecast Year [2032] USD 152.08 million
CAGR (%) 12.23%

Leukapheresis has emerged as an essential procedural platform at the intersection of hematology, immunology, and regenerative medicine, serving both diagnostic and therapeutic needs. As clinical teams increasingly rely on apheresis-derived cellular products for cellular therapies and immune monitoring, institutions must balance procedural complexity with clinical benefit. Technological innovation has lowered barriers to adoption, while regulatory and reimbursement environments continue to shape deployment at hospitals, specialty clinics, and research centers.

Over recent years, practitioners and procurement professionals have placed heightened emphasis on device interoperability, process standardization, and supply chain resilience. These priorities have accelerated collaborations among device manufacturers, consumables suppliers, and clinical research organizations to ensure reproducible cell collection and processing. Moreover, the rise of cellular therapy programs has translated operational focus toward integrating apheresis systems with downstream manufacturing workflows, thereby elevating the importance of monitoring devices and consumable quality.

Looking ahead, program leaders will need to navigate evolving clinical indications, integration of continuous and discontinuous flow technologies, and workforce training to scale service lines sustainably. In response, stakeholders are prioritizing modular solutions that support diagnostic blood analysis, immune monitoring, and therapeutic collections while enabling research applications in stem cell science and oncology.

Major transformative shifts in clinical demand, device innovation, and regulatory emphasis that are redefining leukapheresis practice and procurement strategies

The leukapheresis landscape is undergoing transformative shifts driven by converging forces across clinical demand, technology development, and regulatory emphasis. As cellular therapies mature, clinical teams are expanding indications beyond traditional hematologic uses into broader autoimmune and oncology applications, prompting devices and consumable suppliers to refine performance, usability, and safety features. This evolution is evident in the proliferation of systems designed for streamlined workflows and improved patient comfort, along with monitoring devices that deliver real-time process metrics supporting quality assurance.

Concurrently, advances in anticoagulant chemistry and kit standardization have reduced variability in collected cell populations and improved downstream manufacturing compatibility. In research settings, there is a discernible pivot toward configurable platforms that support both diagnostic workflows-such as blood analysis and immune monitoring-and specialized research needs for stem cell and cellular therapy programs. Such dual-use capabilities increase the value proposition for institutions that must support cross-functional teams within constrained capital budgets.

Regulatory scrutiny and payer evaluation are also reshaping product development roadmaps, encouraging suppliers to embed traceability, data capture, and compliance-ready features into devices and consumables. Consequently, strategic partnerships among device manufacturers, clinical centers, and research institutes are becoming more common, reflecting a collaborative approach to accelerating clinical adoption while maintaining patient safety and operational efficiency.

Implications of recent United States tariff developments on procurement planning, supply chain strategies, and equipment sourcing across leukapheresis operations

Recent trade policy adjustments and tariff developments in the United States have introduced new considerations for supply chain and procurement planning across the leukapheresis ecosystem. Import duties and classification changes affecting components, instruments, and finished devices have the potential to incrementally raise landed costs for certain consumables and equipment. As a result, hospital procurement teams and research institutions are reassessing sourcing strategies to preserve budgetary flexibility while ensuring uninterrupted access to critical supplies.

In reaction to tariff-driven cost pressures, several stakeholders are exploring nearshoring of component manufacturing and strengthening relationships with domestic or regionally based suppliers to reduce exposure to cross-border tariff volatility. At the same time, manufacturers are responding by reviewing global manufacturing footprints, seeking tariff mitigation through product reclassification where appropriate, and optimizing packaging and logistics to limit cost impacts. These adjustments frequently include renegotiating supplier contracts and revisiting inventory strategies to buffer short-term price variability.

Importantly, tariff dynamics also influence long-term capital planning, with equipment buyers weighing total cost of ownership and serviceability in an environment of fluctuating import expenses. Therefore, procurement leaders must integrate trade policy monitoring into capital acquisition timelines and partner with clinical engineering and supply chain teams to identify resilient sourcing pathways that align with institutional priorities and regulatory compliance needs.

Comprehensive segmentation insights revealing component, application, end-user, disease indication, and technology priorities that drive product and service strategies

A nuanced understanding of segment-specific drivers is critical for stakeholders seeking to align product development and service delivery with clinical and research demand. Based on Component, the landscape is studied across Consumables and Equipment, with Consumables further divided into Anticoagulants and Kits while Equipment is analyzed across Apheresis Systems and Monitoring Devices, highlighting where standardization and quality control are most impactful. Based on Application, the ecosystem spans Diagnostic, Research, and Therapeutic uses, with Diagnostic further exploring Blood Analysis and Immune Monitoring, Research encompassing Cellular Therapy and Stem Cell Research, and Therapeutic covering Autoimmune and Oncology indications, indicating diverse end-to-end workflows and differing regulatory expectations.

Based on End User, adoption patterns vary across Hospitals, Research Institutes, and Specialty Clinics, each of which presents distinct procurement cycles, clinical throughput demands, and staffing models. Based on Disease Indication, clinical priorities are driven by Autoimmune Diseases, Leukemia, and Solid Tumors, with Autoimmune Diseases further detailed into Multiple Sclerosis and Rheumatoid Arthritis, underscoring the differing therapeutic protocols and collection requirements. Based on Technology, the field is shaped by Continuous Flow and Discontinuous Flow platforms, which present trade-offs in throughput, patient experience, and integration complexity.

Together, these segmentation lenses reveal where innovation yields operational leverage, where regulatory alignment is most critical, and where tailored commercial models-ranging from consumable re-supply agreements to capital-as-a-service-can unlock adoption. Stakeholders who map their product roadmaps and service models to these segment-specific realities will better meet clinician needs and institutional constraints.

Regional dynamics and strategic considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape adoption, service, and evidence strategies

Regional dynamics exert a material influence on adoption trajectories, reimbursement pathways, and strategic partnerships across the leukapheresis value chain. In the Americas, clinical networks and large hospital systems often lead in integrating apheresis into therapeutic protocols and cellular therapy programs, supported by established supply chains and a robust service infrastructure. These conditions create fertile ground for scalable implementations and collaboration between clinical researchers and industry partners.

Across Europe, Middle East & Africa, regulatory harmonization efforts, diverse payer environments, and variable healthcare infrastructure shape differentiated adoption patterns. In parts of Europe, strong health technology assessment processes and centralized procurement influence device selection and consumable standardization, while regions in the Middle East and Africa may prioritize modular, serviceable solutions that can operate within constrained logistics and maintenance frameworks. In contrast, Asia-Pacific presents a heterogeneous landscape where rapidly expanding clinical research activity, a growing number of cellular therapy centers, and localized manufacturing investments accelerate adoption in certain markets while other territories await infrastructure development.

Consequently, commercial strategies must adapt to local reimbursement models, training requirements, and service network maturity. Companies and clinical leaders alike benefit from regionally tailored clinical evidence packages, flexible commercial terms, and investments in local technical support to achieve sustained program growth and patient access across these distinct geographies.

Key corporate strategies and partnership models among device makers, consumable suppliers, and service providers that accelerate clinical integration and operational resilience

Leading organizations across the device, consumable, and services spectrum are aligning product development with clinical workflows to reduce procedural complexity and improve data continuity. Manufacturers are increasingly prioritizing interoperability with electronic health records and laboratory information systems to enable traceability from collection through downstream processing. Meanwhile, consumable suppliers have focused on kit standardization and anticoagulant optimization to reduce variability in cell yields and enhance compatibility with cellular therapy manufacturing processes.

Strategic partnerships between equipment suppliers and research institutes have become more common, as collaboration accelerates clinical validation and supports investigator-initiated studies. Service providers are differentiating on technician training programs, preventive maintenance networks, and rapid-response field service to minimize downtime and support clinical throughput. Additionally, several companies are investing in digital monitoring tools that collect process metrics and patient data to support quality assurance, regulatory documentation, and continuous improvement initiatives.

From a commercial perspective, vendors that demonstrate clear total cost of operation benefits, strong clinical evidence, and robust post-sale support tend to achieve deeper institutional penetration. Similarly, organizations that offer flexible financing, consumable subscription models, and integrated training resources position themselves as long-term partners for hospitals, specialty clinics, and research centers seeking to expand apheresis capabilities.

Actionable recommendations for industry executives to align clinical performance, supply chain resilience, and commercial flexibility for scalable leukapheresis programs

Industry leaders should adopt a multifaceted strategy that balances clinical performance, supply chain resilience, and commercial flexibility to capture long-term value. First, invest in interoperability and data capture capabilities to ensure traceability from collection through downstream processing, thereby strengthening clinical evidence generation and regulatory readiness. Second, diversify sourcing by qualifying regional suppliers and exploring nearshoring opportunities to mitigate exposure to trade policy shifts and to shorten lead times for critical consumables.

Third, prioritize user-centered design and training initiatives to lower the operational burden on clinical teams and to scale procedural adoption across hospitals and specialty clinics. Fourth, develop flexible commercial offerings, including consumable subscription models and equipment-as-a-service options, to address capital constraints and to align supplier incentives with operational outcomes. Fifth, cultivate collaborative research partnerships with academic centers and clinical networks to co-develop evidence that supports expanded therapeutic indications and reimbursement discussions.

By implementing these actions in a coordinated fashion and by integrating supply chain, clinical, and commercial planning, industry participants can improve adoption velocity, reduce operational friction, and enhance the long-term sustainability of leukapheresis programs across diverse healthcare settings.

Research methodology integrating primary stakeholder interviews, secondary technical literature review, and regulatory analysis to ensure actionable and verifiable findings

This research synthesized primary interviews with clinical leaders, procurement specialists, and device engineers, complemented by secondary analysis of clinical trial registries, regulatory filings, and peer-reviewed literature to form a multi-dimensional view of the leukapheresis landscape. Primary engagement included structured discussions with hospital blood bank directors, cellular therapy program leads, and research institute administrators to validate operational challenges, procurement preferences, and clinical integration priorities.

Secondary sources provided a rigorous technical baseline for device classifications, anticoagulant chemistries, and procedural workflows, while regulatory documents and guidance notes helped contextualize compliance and data traceability requirements. Triangulation across these inputs ensured that insights reflected both frontline operational realities and broader technological trajectories. Throughout the process, attention was paid to regional differences in reimbursement and service infrastructure to produce actionable, context-sensitive conclusions.

Quality control measures included cross-validation of interview findings, review of clinical protocols, and consultation with subject-matter experts in apheresis technology and cellular therapy manufacturing. This layered approach yielded findings grounded in practitioner experience and documented technical evidence while ensuring methodological transparency for decision-makers seeking to apply the insights within their organizations.

Conclusion synthesizing clinical, operational, and commercial imperatives to guide sustainable expansion and adoption of leukapheresis programs

In summary, leukapheresis sits at a strategic inflection point where clinical demand, technological innovation, and supply chain dynamics converge to shape future program models. The convergence of diagnostic and therapeutic applications demands devices and consumables that can deliver reproducible collections, robust monitoring, and seamless integration with downstream manufacturing and laboratory workflows. At the same time, evolving trade policies and regional healthcare variability require procurement teams and vendors to adopt resilient sourcing and commercially adaptable approaches.

Stakeholders that prioritize interoperability, evidence generation, and flexible commercial models will be best positioned to meet the operational needs of hospitals, research institutes, and specialty clinics. Furthermore, targeted investments in user training, preventive maintenance networks, and localized support structures will reduce downtime and improve clinical throughput. Collaboration across manufacturers, clinical research centers, and payers will accelerate the translation of apheresis-enabled therapies to broader patient populations while maintaining a focus on safety and quality.

Ultimately, a coordinated strategy that balances clinical performance, operational resilience, and commercial pragmatism will enable institutions to scale leukapheresis capabilities in ways that sustain long-term program growth and enhance patient access to advanced cellular and immunologic therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Leukapheresis Market, by Component

  • 8.1. Consumables
    • 8.1.1. Anticoagulants
    • 8.1.2. Kits
  • 8.2. Equipment
    • 8.2.1. Apheresis Systems
    • 8.2.2. Monitoring Devices

9. Leukapheresis Market, by Disease Indication

  • 9.1. Autoimmune Diseases
    • 9.1.1. Multiple Sclerosis
    • 9.1.2. Rheumatoid Arthritis
  • 9.2. Leukemia
  • 9.3. Solid Tumors

10. Leukapheresis Market, by Technology

  • 10.1. Continuous Flow
  • 10.2. Discontinuous Flow

11. Leukapheresis Market, by Application

  • 11.1. Diagnostic
    • 11.1.1. Blood Analysis
    • 11.1.2. Immune Monitoring
  • 11.2. Research
    • 11.2.1. Cellular Therapy
    • 11.2.2. Stem Cell Research
  • 11.3. Therapeutic
    • 11.3.1. Autoimmune
    • 11.3.2. Oncology

12. Leukapheresis Market, by End User

  • 12.1. Hospitals
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Leukapheresis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Leukapheresis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Leukapheresis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Leukapheresis Market

17. China Leukapheresis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Allcells, LLC
  • 18.6. Asahi Kasei Corporation
  • 18.7. B. Braun Melsungen AG
  • 18.8. Beijing Zksk Technology Co. Ltd.
  • 18.9. Bioivt
  • 18.10. Caltag Medsystems Limited
  • 18.11. Charles River Laboratories International, Inc.
  • 18.12. Danaher Corporation
  • 18.13. Discovery Life Sciences
  • 18.14. Fresenius Kabi AG
  • 18.15. Guangzhou Daji Medical Science and Technology Co. Ltd.
  • 18.16. Haemonetics Corporation
  • 18.17. Intelligent Tissue Group
  • 18.18. Lonza Group Ag
  • 18.19. Macopharma SA
  • 18.20. Medica Spa.
  • 18.21. Miltenyi Biotec GmbH
  • 18.22. Precision for Medicine, Inc.
  • 18.23. Puriblood Medical Co. Ltd.
  • 18.24. Stemexpress, LLC
  • 18.25. Terumo BCT
  • 18.26. Zenbio, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LEUKAPHERESIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LEUKAPHERESIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LEUKAPHERESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LEUKAPHERESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LEUKAPHERESIS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LEUKAPHERESIS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LEUKAPHERESIS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APHERESIS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APHERESIS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APHERESIS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LEUKAPHERESIS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LEUKAPHERESIS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LEUKAPHERESIS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISCONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISCONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISCONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LEUKAPHERESIS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LEUKAPHERESIS MARKET SIZE, BY BLOOD ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LEUKAPHERESIS MARKET SIZE, BY BLOOD ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LEUKAPHERESIS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LEUKAPHERESIS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LEUKAPHERESIS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CELLULAR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CELLULAR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CELLULAR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LEUKAPHERESIS MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LEUKAPHERESIS MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LEUKAPHERESIS MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LEUKAPHERESIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LEUKAPHERESIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LEUKAPHERESIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LEUKAPHERESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LEUKAPHERESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL LEUKAPHERESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 200. GCC LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. GCC LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 207. GCC LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 208. GCC LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 209. GCC LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 236. G7 LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 238. G7 LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 243. G7 LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 244. G7 LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 245. G7 LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. NATO LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 248. NATO LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. NATO LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 250. NATO LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. NATO LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. NATO LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 255. NATO LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 256. NATO LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 257. NATO LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA LEUKAPHERESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)